Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma

Sponsor
Peking University People's Hospital
Study ID
NCT07620431
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Bone Neoplasms
  • Ewing Sarcoma

Eligibility Criteria

Sex
ALL
Age
12 Months - N/A
Healthy Volunteers
Not accepted

Study Details

This is a single-center, single-arm, prospective observational study to evaluate the long-term local control rate, safety, and efficacy of preoperative neoadjuvant radiotherapy (36-45 Gy) followed by sequential radical surgery and postoperative chemotherapy in patients with high-risk, resectable localized Ewing sarcoma.

Key Dates

First listed
Jun 2, 2026
Start date
Jun 1, 2026
Status verified
May 2026
Primary completion
Dec 1, 2027
Completion
Dec 1, 2027

Study Design

Enrollment
55 participants (estimated)

Primary Outcome Measure

Local Recurrence-Free Survival (LRFS) [ Time Frame: From the date of surgery up to the date of first documented local recurrence or death from any cause, assessed up to 5 years post-surgery. ]

Central Contacts

Related Studies